Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s383. https://doi.org/10.25251/skin.8.supp.383